Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
NEW YORK, March 03, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Endologix, Inc. (NASDAQ:ELGX) securities between August 2, 2016 and November 16, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/endologix-inc. There is no cost or obligation to you.
According to the complaint, defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix EndoVascular Aneurysm Sealing System; and (2) as a result, Endologix’s public statements were materially false and misleading at all relevant times.
On November 16, 2016, Endologix announced that the FDA requested two-year follow-up data on patients enrolled in the EVAS-FORWARD IDE study to assess Nellix. On this news, shares of Endologix fell $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016, damaging investors.
If you suffered a loss in Endologix you have until March 6, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/endologix-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
